April 20, 2018 09:07 AM EDT

With Gilenya generics looming, Novartis’ siponimod team buffs up the MS data package being prepped for the FDA

John Carroll

Editor & Founder

Researchers for Novartis $NVS turned up at the 70th American Academy of Neurology annual meeting in LA Friday to polish up their pivotal data package …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With Gilenya generics looming, Novartis’ siponimod team buffs up the MS data package being prepped for the FDA

John Carroll

Editor & Founder

Sign up to read this article for free.

Pfizer looking to sell hospital drugs unit — reports

'Expertise is a real thing': FDA commissioner warns of political risk to agency

Merck, AstraZeneca tout Phase 3 win for cancer-turned-rare disease drug

AstraZeneca CEO reaffirms commitment to China following executive's detention

Sanofi, OpenAI, Formation Bio debut patient recruiting tool, will use in Phase 3 multiple sclerosis studies

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

With Gilenya gener­ics loom­ing, No­var­tis’ sipon­i­mod team buffs up the MS da­ta pack­age be­ing prepped for the FDA

John Carroll

Editor & Founder

Sign up to read this article for free.

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

With Gilenya generics looming, Novartis’ siponimod team buffs up the MS data package being prepped for the FDA

Pfizer looking to sell hospital drugs unit — reports

'Expertise is a real thing': FDA commissioner warns of political risk to agency

Merck, AstraZeneca tout Phase 3 win for cancer-turned-rare disease drug

AstraZeneca CEO reaffirms commitment to China following executive's detention

Sanofi, OpenAI, Formation Bio debut patient recruiting tool, will use in Phase 3 multiple sclerosis studies

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?